Background: Continuous subcutaneous levodopa infusion is an established option for advanced Parkinson's disease (PD). Subcutaneous levodopa/carbidopa infusion (ND0612) and foslevodopa/foscarbidopa (ABBV-951) are available infusion systems; however, no clinical guidance exists regarding conversion between these treatments.Methods: We report two patients with advanced PD receiving ND0612 in combination with oral levodopa who underwent complete transition to ABBV-951. Initial foslevodopa/foscarbidopa dosing was estimated according to levodopa equivalent daily dose and subsequently titrated under close neurological supervision. Motor fluctuations, non-motor symptoms, quality of life, and infusion-site tolerability were evaluated at baseline and at 3-month follow-up using standardized clinical assessments.Results: Both transitions were completed within one day without acute adverse events. At three months, both patients showed a marked reduction in daily off time, improvement in dyskinesias and freezing of gait, and stabilization of sleep and behavioral symptoms. ABBV-951 demonstrated improved local tolerability, with no infusion-site complications observed during follow-up.Conclusions: Conversion from ND0612 to ABBV-951 appears feasible, and safe in advanced PD. These preliminary observations may provide practical insight in the absence of published data addressing this specific therapeutic transition.
Transition from subcutaneous levodopa/carbidopa (ND0612) to Foslevodopa/Foscarbidopa in advanced Parkinson's disease
De Rosa M. A.;Russo M.;Thomas A.;Sensi S. L.
2026-01-01
Abstract
Background: Continuous subcutaneous levodopa infusion is an established option for advanced Parkinson's disease (PD). Subcutaneous levodopa/carbidopa infusion (ND0612) and foslevodopa/foscarbidopa (ABBV-951) are available infusion systems; however, no clinical guidance exists regarding conversion between these treatments.Methods: We report two patients with advanced PD receiving ND0612 in combination with oral levodopa who underwent complete transition to ABBV-951. Initial foslevodopa/foscarbidopa dosing was estimated according to levodopa equivalent daily dose and subsequently titrated under close neurological supervision. Motor fluctuations, non-motor symptoms, quality of life, and infusion-site tolerability were evaluated at baseline and at 3-month follow-up using standardized clinical assessments.Results: Both transitions were completed within one day without acute adverse events. At three months, both patients showed a marked reduction in daily off time, improvement in dyskinesias and freezing of gait, and stabilization of sleep and behavioral symptoms. ABBV-951 demonstrated improved local tolerability, with no infusion-site complications observed during follow-up.Conclusions: Conversion from ND0612 to ABBV-951 appears feasible, and safe in advanced PD. These preliminary observations may provide practical insight in the absence of published data addressing this specific therapeutic transition.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
